Carbon nanotubes in COVID-19: A critical review and prospects-Reference-Cited by-同舟云学术

Carbon nanotubes in COVID-19: A critical review and prospects

Published:2022-01 Issue: Volume:46 Page:100544
ISSN:2215-0382
Container-title:Colloid and Interface Science Communications
language:en
Short-container-title:Colloid and Interface Science Communications

Author:

Varghese Ryan,Salvi Sahil,Sood Purab,Karsiya Jainam,Kumar Dileep

Publisher

Elsevier BV

Subject

Materials Chemistry,Colloid and Surface Chemistry,Surfaces, Coatings and Films,Physical and Theoretical Chemistry,Biotechnology

Reference51 articles.

1. COVID-19 in early 2021: current status and looking forward. Signal Transduction and Targeted Therapy [Internet];Wang,2021

2. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19);Ahn;J. Microbiol. Biotechnol.,2020

3. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgraduate Medical Journal [Internet];Parasher;BMJ,2020

4. COVID-19 pathophysiology: A review. Clinical Immunology [Internet];Yuki;Elsevier BV,2020

5. First Case of 2019 Novel Coronavirus in the United States;Holshue;N. Engl. J. Med.,2020

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single‐Walled Carbon Nanotube‐Based Optical Nano/Biosensors for Biomedical Applications: Role in Bioimaging, Disease Diagnosis, and Biomarkers Detection;Advanced Materials Technologies;2024-05-16

2. Emerging Trends of Gold Nanostructures for Point-of-Care Biosensor-Based Detection of COVID-19;Molecular Biotechnology;2024-05-04

3. Current advances in the therapeutic potential of nanomedicines for pulmonary disorders;Emergent Materials;2024-04-24

4. Bio-actives and COVID-19: a production of sustainable fermented ginger beer and probiotic fruit drinks as a plausible approach for boosting the immune system;Discover Food;2024-01-29

5. Cubosomes: The Next Generation of Nanomedicine Delivery Systems in Cancer Treatment;J BIOL REG HOMEOS AG;2024